Large equity awards to Elisabet de los Pinos at Aura Biosciences (AURA)

Rhea-AI Filing Summary

Aura Biosciences reported new equity awards to director and officer Elisabet de los Pinos. On March 2, 2026, she acquired 166,000 shares of Common Stock through a restricted stock unit award at a grant price of $0.0000 per share, increasing her directly held Common Stock to 575,815 shares.

She also received a stock option for 249,000 shares of Common Stock at an exercise price of $0.0000 per share, with 249,000 option shares outstanding after the award. The RSUs vest in four substantially equal annual installments beginning on January 15, 2027, and the option vests 25% on February 1, 2027, with the remainder vesting pro rata in 36 monthly installments, in each case subject to her continued service.

Separately, 127,763 Common shares are held indirectly by the Elisabet de los Pinos Revocable Trust dated April 8, 2016, of which she is a trustee.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

de los Pinos Elisabet

(Last) (First) (Middle)

C/O AURA BIOSCIENCES, INC.

80 GUEST STREET

(Street)

BOSTON MA 02135

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aura Biosciences, Inc. [ AURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		A		166,000(1)	A	$0	575,815	D
Common Stock								127,763	I	By EdIP Revocable Trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.14	03/02/2026		A		249,000		(3)	03/02/2036	Common Stock	249,000	$0	249,000	D

Explanation of Responses:

1. These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date.

2. The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee.

3. The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.

Remarks:

President and Chief Executive Officer

	/s/ Conor Kilroy, as Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does Aura Biosciences (AURA) latest Form 4 show for Elisabet de los Pinos?

The Form 4 shows Elisabet de los Pinos received new equity awards, including 166,000 restricted stock units and a 249,000-share stock option, and reports updated direct and indirect Common Stock holdings through personal ownership and a revocable trust.

How many Aura Biosciences (AURA) RSUs and options were granted in this Form 4?

Elisabet de los Pinos was granted 166,000 restricted stock units of Aura Biosciences Common Stock and a stock option covering 249,000 shares, both at a grant or exercise price of $0.0000 per share, subject to multi-year vesting schedules tied to continued service.

What are the vesting terms of the Aura Biosciences (AURA) RSU grant reported?

The 166,000 RSUs vest in four substantially equal annual installments beginning on January 15, 2027. Each installment requires Elisabet de los Pinos to remain in service through the applicable vesting date under Aura Biosciences’ 2021 Stock Option and Incentive Plan.

How do the Aura Biosciences (AURA) stock options in this filing vest over time?

The 249,000-share stock option vests with 25% of the shares on February 1, 2027. The remaining shares vest pro rata in 36 monthly installments thereafter, contingent on Elisabet de los Pinos continuing to serve Aura Biosciences through each vesting date.

How many Aura Biosciences (AURA) shares does Elisabet de los Pinos own directly and indirectly after these transactions?

After these transactions, she directly holds 575,815 shares of Aura Biosciences Common Stock and indirectly holds 127,763 shares through the Elisabet de los Pinos Revocable Trust dated April 8, 2016, for which she serves as trustee.

What is the role of the Elisabet de los Pinos Revocable Trust in Aura Biosciences (AURA) ownership?

The Elisabet de los Pinos Revocable Trust dated April 8, 2016 holds 127,763 Aura Biosciences Common shares. Elisabet de los Pinos is a trustee of this trust, and the filing reports these shares as indirectly owned through the trust structure.